Paulex Bio Announces Registration of Phase 1/2a Trial of PAL-119, an Oral Small Molecule Designed to Regenerate and Restore the Function of Insulin-Producing Beta Cells

The Quick Take
First-in-human study plans to enroll healthy volunteers and adults with Type 1 or Type 2 diabetes to evaluate PAL-119's safety and tolerability and explore its effects on the body's own insulin production SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Paulex Bio Inc., a biopharmaceutical company...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Education Couture Announces Inaugural LIT CHICAGO Advisory Council
In celebration of National Family Literacy Month, Toussaint Daniels and Terry Roseland join a citywide literacy initiative. CHICAGO, Nov. 2, 2026 /PRNewswire/…
Business
5 Tips to Help Local Shops, Restaurant Make the Most of Small Business Saturday - NFIB
5 Tips to Help Local Shops, Restaurant Make the Most of Small Business Saturday NFIB
Business
Coming Soon: TheraCopper Expands Its Drinkware Collection with Six New Copper Designs
ROCHESTER, Mich., Nov. 2, 2026 /PRNewswire/ -- TheraCopper, a copper specialist that has built pure-copper products since 2015, today announced that a new…
Business
Bold Therapeutics Presents Corporate and BOLD-100 Updates at BIO-Europe in Cologne, Germany
Company leadership will deliver key corporate milestones and clinical advancement data for BOLD-100. VANCOUVER, BC, Nov. 2, 2026 /PRNewswire/ -- Bold…
